Literature DB >> 8906385

The rate of visual recovery after penetrating keratoplasty for keratoconus.

J S Silbiger1, E J Cohen, P R Laibson.   

Abstract

PURPOSE: We performed a retrospective study of 68 patients who underwent penetrating keratoplasty (PK) for keratoconus during the years of 1988 and 1989. The purpose of this study was to determine the speed of visual recovery, final best corrected visual acuity, and rate of rejection episodes.
METHODS: The visual acuity, type of correction, and complications were recorded at 3, 6, 12, 18, 24, 36, and 48 months.
RESULTS: The average final best corrected visual acuity was 20/23, and all patents achieved 20/30 or better vision (range: 20/15 to 20/30). The best vision was achieved at 16.5 +/- 8.7 months. Thirty-one percent of the patients were corrected with contact lenses. Factors associated with best corrected vision were preoperative vision, combined suture technique, and a donor/host size disparity of 0.25 mm (P < 0.005). Thirty-one percent of the patients had at least one episode of graft rejection. The use of contact lenses was not associated with an increased risk of rejection.
CONCLUSIONS: PK for keratoconus yields an excellent visual result, but this study shows the need for long-term careful follow-up to achieve optimal visual rehabilitation.

Entities:  

Mesh:

Year:  1996        PMID: 8906385

Source DB:  PubMed          Journal:  CLAO J        ISSN: 0733-8902


  3 in total

1.  [Satisfaction with penetrating keratoplasty. Results of a questionnaire census].

Authors:  D Böhringer; A Schindler; T Reinhard
Journal:  Ophthalmologe       Date:  2006-08       Impact factor: 1.059

2.  Deep lamellar keratoplasty with lyophilised tissue in the management of keratoconus.

Authors:  A G Coombes; J F Kirwan; C K Rostron
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 3.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.